Tag Archives: Pharma
This post sets out some of the political and legal history of the ban in order to explain why, once the high-minded talk of election season concludes, repeal may be unrealistic, or even unwise.
September 19, 2016
The opioid painkiller epidemic in Colorado was the focus of a session at this year's Colorado Health Symposium. The Colorado Health Foundation hosts this well-known annual forum.
August 25, 2016
For the second year, a small Health Affairs team attended Spotlight Health in beautiful Aspen, Colorado. The topics (opioids, planetary health, healthy eating, etc.) were beyond typical. Here are 7 takeaways.
July 7, 2016
Welcome to “From the Archives,” a Health Affairs Blog series, where we take a timely topic and delve into the literature and history, from a Health Affairs angle, of course. Harvoni, Sovaldi, Repatha, Daraprim. Four drugs that have made news for how much they cost patients and insurers. But...
November 24, 2015
Hundreds of thousands of deaths, heart attacks, and strokes have been prevented due to lower cholesterol, yet many patients are missing out on lipid-lowering therapies. Our outdated "price-per-dose" model of pharmaceutical pricing limits access and produces a number of well-known side effects...
September 30, 2015
A new policy brief from Health Affairs and the Robert Wood Johnson Foundation addresses the Sentinel Initiative, launched in 2014 by the FDA, to proactively and systematically detect and respond to emerging risks in prescription medicines.
June 8, 2015
A new discussion draft of the 21st Century Cures Act, the bipartisan initiative to accelerate development of new medical treatments, includes a section entitled “Facilitating Dissemination of Health Care Economic Information.”
May 15, 2015
The past decade has seen a relatively constant rate of newly approved drugs every year. The number has even jumped in the past few years. Yet, despite such encouraging trends, we are actually facing a crisis in drug innovation today.
April 30, 2015
There is currently a much-needed national spotlight on the high rates of psychotropic medication use among children and youth in foster care, most of whom receive health coverage through Medicaid.
April 17, 2015
One critical incentive for ongoing drug discovery and development is the temporary monopoly pricing that manufacturers can command for novel drugs. Yet this incentive, embedded in current patent and regulatory policy, does not guarantee that manufacturers will deliver novel products with...
April 16, 2015